STOCK TITAN
  1. Home
  2. Sec-filings
  3. TEVA
  4. [Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Teva (TEVA) CAO Weiss boosts stake with RSU vesting and new grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Teva Pharmaceutical Industries’ Chief Accounting Officer, Amir Weiss, reported equity-based compensation activity on March 4, 2026. He exercised previously granted restricted share units (RSUs), converting 10,679 RSUs from a 2022 grant and 5,650 RSUs from a 2024 grant into the same number of ordinary shares at no cash cost.

Weiss also received a new award of 11,280 RSUs granted on March 4, 2026, scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030. Following these transactions, he directly owned 27,158 ordinary shares and 11,280 RSUs, reflecting increased equity exposure with no reported share sales.

Positive

  • None.

Negative

  • None.
Insider Weiss Amir
Role Chief Accounting Officer
Type Security Shares Price Value
Exercise Restricted Share Units 10,679 $0.00 --
Exercise Restricted Share Units 5,650 $0.00 --
Grant/Award Restricted Share Units 11,280 $0.00 --
Exercise Ordinary Shares 10,679 $0.00 --
Exercise Ordinary Shares 5,650 $0.00 --
Holdings After Transaction: Restricted Share Units — 0 shares (Direct); Ordinary Shares — 21,508 shares (Direct)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vested on March 4, 2026. Restricted share units were granted on March 4, 2024, with 5,650 vested on each of March 4, 2025 and March 4, 2026, and 5,650 vesting on each of March 4, 2027 and March 4, 2028. Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Weiss Amir
(Last) (First) (Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
(Street)
TEL AVIV L3 6944020
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 03/04/2026 M 10,679 A (2) 21,508 D
Ordinary Shares(1) 03/04/2026 M 5,650 A (2) 27,158 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units (2) 03/04/2026 M 10,679 (3) (3) Ordinary Shares(1) 10,679 $0 0 D
Restricted Share Units (2) 03/04/2026 M 5,650 (4) (4) Ordinary Shares(1) 5,650 $0 11,300 D
Restricted Share Units (2) 03/04/2026 A 11,280 (5) (5) Ordinary Shares(1) 11,280 $0 11,280 D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. Restricted share units were granted on March 4, 2022, with 10,676 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 10,679 vested on March 4, 2026.
4. Restricted share units were granted on March 4, 2024, with 5,650 vested on each of March 4, 2025 and March 4, 2026, and 5,650 vesting on each of March 4, 2027 and March 4, 2028.
5. Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss 03/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Teva (TEVA) Chief Accounting Officer Amir Weiss report?

Amir Weiss reported equity awards and vesting-related activity, not open-market trades. On March 4, 2026, he converted previously granted restricted share units into ordinary shares and received a new restricted share unit grant as part of his compensation package.

How many Teva shares did Amir Weiss acquire through RSU vesting?

Weiss acquired ordinary shares through vesting of 10,679 restricted share units from a 2022 grant and 5,650 restricted share units from a 2024 grant, all on March 4, 2026. Each vested unit delivered one ordinary share or its cash value at settlement.

What new equity award did Amir Weiss receive from Teva (TEVA)?

On March 4, 2026, Weiss received a new grant of 11,280 restricted share units. These units are scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030, subject to the award’s terms.

What is Amir Weiss’s Teva equity ownership after these Form 4 transactions?

After the March 4, 2026 activity, Weiss directly held 27,158 Teva ordinary shares and 11,280 restricted share units. This reflects his accumulated vested share ownership plus the new unvested RSU grant reported in the insider filing.

Were there any Teva share sales reported by Amir Weiss in this Form 4?

No share sales were reported. All transactions were coded as acquisitions, including exercises or conversions of restricted share units into ordinary shares and a new restricted share unit grant. The filing shows increased equity exposure rather than a reduction.

How do Teva restricted share units reported by Amir Weiss settle?

Each restricted share unit represents a contingent right to receive, at settlement, one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, according to the footnote in the Form 4 filing.